Motolimod
- Generic Name
- Motolimod
- Drug Type
- Small Molecule
- Chemical Formula
- C28H34N4O2
- CAS Number
- 926927-61-9
- Unique Ingredient Identifier
- WP6PY72ZH3
- Background
Motolimod has been used in trials studying the treatment of Lymphoma, Tongue Cancer, Ovarian Cancer, Adult Solid Neoplasm, and Fallopian Tube Cancer, among others.
Intratumoral Microdosing of Motolimod in HNSCC
- Conditions
- HNSCC
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Presage Biosciences
- Target Recruit Count
- 1
- Registration Number
- NCT04272333
- Locations
- ๐บ๐ธ
University of California, San Francisco, San Francisco, California, United States
๐บ๐ธUniversity of Illinois at Chicago, Chicago, Illinois, United States
๐บ๐ธOregon Health & Science University (OHSU), Portland, Oregon, United States
A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 15
- Registration Number
- NCT03906526
- Locations
- ๐บ๐ธ
Local Institution - 103, Sioux Falls, South Dakota, United States
๐บ๐ธUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธUniversity of Cincinnati, Cincinnati, Ohio, United States
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 53
- Registration Number
- NCT02431559
- Locations
- ๐บ๐ธ
Research Facitlity, Phoenix, Arizona, United States
๐จ๐ญResearch Facility, Lausanne, Switzerland
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2019-10-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 18
- Registration Number
- NCT02124850
- Locations
- ๐บ๐ธ
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Carcinoma, Squamous Cell of Head and Neck
- Interventions
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 195
- Registration Number
- NCT01836029
- Locations
- ๐บ๐ธ
Winship Cancer Institute, Atlanta, Georgia, United States
๐บ๐ธUniversity of Kansas Cancer Center, Westwood, Kansas, United States
๐บ๐ธUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Conditions
- Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
- Interventions
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 297
- Registration Number
- NCT01666444
- Locations
- ๐บ๐ธ
Ohio State University Medical Center, Columbus, Ohio, United States
๐บ๐ธAspirus Regional Cancer Center, Wausau, Wisconsin, United States
๐บ๐ธJohns Hopkins Medical Institution, Baltimore, Maryland, United States
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
- Conditions
- Advanced Solid TumorsLymphoma
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 33
- Registration Number
- NCT00688415
- Locations
- ๐บ๐ธ
Mayo Clinic, Scottsdale, Arizona, United States
๐บ๐ธScottsdale Healthcare, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.